Efficacy of kisspeptin-54 to trigger Oocyte maturation in women at high risk of ovarian hyperstimulation syndrome (OHSS) during in vitro fertilization (IVF) therapy

Journal of Clinical Endocrinology and Metabolism

Volumn 100, Issue 9, 2015, Pages 3322-3331

  Abbara, Ali ^a   Jayasena, Channa N ^a   Christopoulos, Georgios ^a   Narayanaswamy, Shakunthala ^a   Izzi Engbeaya, Chioma ^a   Nijher, Gurjinder M K ^a   Comninos, Alexander N ^a   Peters, Deborah ^a   Buckley, Adam ^a   Ratnasabapathy, Risheka ^a   Prague, Julia K ^a   Salim, Rehan ^a   Lavery, Stuart A ^a   Bloom, Stephen R ^a   Szigeti, Matyas ^b   Ashby, Deborah A ^b   Trew, Geoffrey H ^a   Dhillo, Waljit S ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b ST MARY S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

METASTIN; FOLLITROPIN; GONADORELIN; HORMONE ANTAGONIST; KISS1 PROTEIN, HUMAN; KISSPEPTIN;

ADULT; ARTICLE; BIRTH RATE; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; ECTOPIC PREGNANCY; EMBRYO TRANSFER; FEMALE; FERTILIZATION IN VITRO; GESTATIONAL AGE; HIGH RISK POPULATION; HUMAN; INTRACYTOPLASMIC SPERM INJECTION; LIVE BIRTH; MAJOR CLINICAL STUDY; OOCYTE MATURATION; OUTCOME ASSESSMENT; OVARY FOLLICLE CELL; OVARY HYPERSTIMULATION; PHASE 2 CLINICAL TRIAL; PREGNANCY OUTCOME; PREGNANCY RATE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SPONTANEOUS ABORTION; STILLBIRTH; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; CLINICAL TRIAL; DRUG COMBINATION; INFERTILITY, FEMALE; OVARIAN HYPERSTIMULATION SYNDROME; OVULATION INDUCTION; PREGNANCY; PROCEDURES; RISK FACTOR;

ADULT; DRUG THERAPY, COMBINATION; FEMALE; FERTILIZATION IN VITRO; FOLLICLE STIMULATING HORMONE; GONADOTROPIN-RELEASING HORMONE; HORMONE ANTAGONISTS; HUMANS; INFERTILITY, FEMALE; KISSPEPTINS; OVARIAN HYPERSTIMULATION SYNDROME; OVULATION INDUCTION; PREGNANCY; RISK FACTORS;

EID: 84941703071     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2015-2332     Document Type: Article

References (30)

1. Fertility treatment in 2013: Trends and figures; Human Fertilisation Embryology Authority. Available from http://www.hfea.gov.uk/docs/HFEA-Fertility-Trends-and-Figures-2013.pdf
2. Kawwass JF, Kissin DM, Kulkarni AD, et al. Safety of assisted reproductive technology in the United States, 2000-2011. JAMA. 2015;313(1):88-90.
3. RCOG Guideline No.5. The Management of Ovarian Hyperstimulation Syndrome. 2006. Available from https://www.rcog.org.uk/globalassets/documents/guidelines/gtg5-230611.pdf. Accessed 14/04/2015.
4. Delvigne A, Rozenberg S. Epidemiology and prevention of ovarian hyperstimulation syndrome (OHSS): A review. Hum Reprod Update. 2002;8(6):559-577.
5. Wada I, Matson PL, Troup SA, Lieberman BA. Assisted conception using buserelin and human menopausal gonadotrophins in women with polycystic ovary syndrome. Br J Obstet Gynaecol. 1993; 100(4):365-369.
6. Seyhan A, Ata B, Polat M, Son WY, Yarali H, Dahan MH. Severe early ovarian hyperstimulation syndrome following GnRH agonist trigger with the addition of 1500 IU hCG.HumReprod. 2013;28(9): 2522-2528.
7. Hoff JD, Quigley ME, Yen SS. Hormonal dynamics at midcycle: A reevaluation. J Clin Endocrinol Metab. 1983;57(4):792-796.
8. DamewoodMD,ShenW,ZacurHA,SchlaffWD,Rock JA, Wallach EE. Disappearance of exogenously administered human chorionic gonadotropin. Fertil Steril. 1989;52(3):398-400.
9. Orvieto R. Ovarian hyperstimulation syndrome-An optimal solution for an unresolved enigma. J Ovarian Res. 2013;6(1):775.
10. Youssef MA, Van der Veen F, Al-Inany HG, et al. Gonadotropinreleasing hormone agonist versus HCG for oocyte triggering in antagonist-assisted reproductive technology. Cochrane Database Syst Rev. 2014;10:CD008046.
11. Macklon NS, Stouffer RL, Giudice LC, Fauser BC. The science behind 25 years of ovarian stimulation for in vitro fertilization. Endocr Rev. 2006;27:170-207.
12. Jayasena CN, Abbara A, Comninos AN, et al. Kisspeptin-54 triggers egg maturation in women undergoing in vitro fertilization. J Clin Invest. 2014;124(8):3667-3677.
13. Irwig MS, Fraley GS, Smith JT, et al. Kisspeptin activation of gonadotropin releasing hormone neurons and regulation of KiSS-1 mRNAin the male rat. Neuroendocrinology. 2004;80(4):264-272.
14. Lee TH, Liu CH, Huang CC, et al. Serum anti-Mllerian hormone and estradiol levels as predictors of ovarian hyperstimulation syndrome in assisted reproduction technology cycles. Hum Reprod. 2008;23(1):160-167.
15. Jayaprakasan K, Chan Y, Islam R, et al. Prediction of in vitro fertilization outcome at different antral follicle count thresholds in a prospective cohort of 1,012 women. Fertil Steril. 2012;98(3):657-663.
16. Golan A, Weissman A. Symposium: Update on prediction and management of OHSS. A modern classification of OHSS. Reprod Biomed Online. 2009;19(1):28-32.
17. Navot D, Bergh PA, Laufer N. Ovarian hyperstimulation syndrome in novel reproductive technologies: Prevention and treatment. Fertil Steril. 1992;58(2):249-261.
18. Humaidan P, Thomsen LH, Alsbjerg B. GnRHa trigger and modified luteal support with one bolus of hCG should be used with caution in extreme responder patients. Hum. Reprod. 2013;28(9): 2593-2594.
19. Humaidan P, Polyzos NP, Alsbjerg B, et al. GnRHa trigger and individualized luteal phase hCG support according to ovarian response to stimulation: two prospective randomized controlled multi-centre studies in IVF patients. Hum Reprod. 2013;28:2511-2521.
20. Papanikolaou EG, Pozzobon C, Kolibianakis EM, Camus M, Tournaye H, Fatemi HM, Van Steirteghem A, Devroey P. Incidence and prediction of ovarian hyperstimulation syndrome in women undergoing gonadotropin-releasing hormone antagonist in vitro fertilization cycles. Fertil Steril. 2006;85(1):112-120.
21. Chang HJ, Suh CS. Ectopic pregnancy after assisted reproductive technology: What are the risk factors? Curr Opin Obstet Gynecol. 2010;22(3):202-207.
22. Ling LP, Phoon JW, Lau MS, et al. GnRH agonist trigger and ovarian hyperstimulation syndrome: Relook at 'freeze-all strategy'. Reprod Biomed Online. 2014;29(3):392-394.
23. Gurbuz AS, Gode F, Ozcimen N, Isik AZ. Gonadotrophin-releasing hormone agonist trigger and freeze-all strategy does not prevent severe ovarian hyperstimulation syndrome: A report of three cases. Reprod Biomed Online. 2014;29(5):541-544.
24. Fatemi HM, Popovic-Todorovic B, Humaidan P, et al. Severe ovarian hyperstimulation syndrome after gonadotropin-releasing hormone (GnRH) agonist trigger and "freeze-all" approach in GnRH antagonist protocol. Fertil Steril. 2014;101(4):1008-1011.
25. Engmann L, DiLuigi A, Schmidt D, Nulsen J, Maier D, Benadiva C. The use of gonadotropin-releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high-risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: A prospective randomized controlled study. Fertil Steril. 2008;89(1):84-91.
26. Iliodromiti S, Lan VT, Tuong HM, Tuan PH, Humaidan P, Nelson SM. Impact of GnRH agonist triggering and intensive luteal steroid support on live-birth rates and ovarian hyperstimulation syndrome: A retrospective cohort study. J Ovarian Res. 2013;6(1):9326.
27. Shapiro BS, Daneshmand ST, Garner FC, Aguirre M, Hudson C. Comparison of "triggers" using leuprolide acetate alone or in combination with low-dosehumanchorionic gonadotropin. Fertil Steril. 2011;95:2715-2717.
28. Thomsen L, Humaidan P. Ovarian hyperstimulation syndrome in the 21st century: The role of gonadotropin-releasing hormone agonist trigger and kisspeptin. Curr Opin Obstet Gynecol. 2015; 27(3):210-214.
29. Cutting R, Morroll D, Roberts SA, Pickering S, Rutherford A, BFS and ACE. Elective single embryo transfer: guidelines for practice British Fertility Society and Association of Clinical Embryologists. Hum Fertil (Camb). 2008;11(3):131-146.
30. Gardner DK, Lane M, Stevens J, Schlenker T, Schoolcraft WB. Blastocyst score affects implantation and pregnancy outcome: towards a single blastocyst transfer. Fertil Steril. 2000;73:1155-1158.